<DOC>
	<DOCNO>NCT02603471</DOCNO>
	<brief_summary>The propose study , HIV positive alcohol dependent adult currently take naltrexone , pilot randomize control trial ( RCT ) examine outcomes 12-week behavioral support program deliver via text-messaging . It expect text messaging intervention reduce alcohol use HIV-risk behavior . The investigator also hypothesize intervention improve adherence HIV treatment naltrexone . To test effect intervention target outcome , 25 participant receive text message intervention compare 25 participant receive informational pamphlet . The pamphlet contain information importance HIV treatment adherence , reduce HIV risk behavior , health consequence associate alcohol use . By provide support maximize HIV treatment regimen naltrexone adherence , couple cop skill promote abstinence alcohol , text message intervention may provide promising , cost-effective , easily deployable behavioral support program alcohol user HIV-infected .</brief_summary>
	<brief_title>Cell Phone Technology Targeting ART Naltrexone Adherence Alcohol Use</brief_title>
	<detailed_description>The aim study : 1 ) implement evaluate 12-week cognitive behavioral therapy ( CBT ) intervention use text messaging via mobile phone technology ( ALC-TXT-CBT ) reduce alcohol use , reduce HIV-risk behavior facilitate medication adherence population alcohol dependent adult HIV-infection 2 ) examine potential mechanisms action ALC-TXT-CBT . The investigator hypothesize ALC-TXT-CBT produce great reduction alcohol use HIV-risk behavior , improve HIV treatment regimen naltrexone ( Vivitrol ) adherence , relative control condition ( informational pamphlet ) . Further , investigator expect ALC-TXT-CBT facilitate great change negative affect , self-efficacy , social support , change associate substance use outcome .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Age 18 old ; 2 . DSMIV diagnosis Alcohol Dependence ; 3 . Use 5 standard drink per drinking day men 4 woman ( past 30 day ) ; 4 . HIVinfected serostatus ; 5 . Able provide inform consent ; 6 . Willing able participate study procedure , 7 . Good general health , case medical/psychiatric condition need ongoing treatment , potential participant care physician provide documented willingness continue participant 's medical management coordinate care study physician . 8 . Adherent &lt; 90 % antiretroviral therapy regimen , determine medication adherence screen procedure 9 . Currently take interested taking/receiving information naltrexone injectable form ( Vivitrol ) . Participants WILL NOT prescribe give naltrexone part study . Participants currently vivitrol referred physician community evaluate vivitrol eligibility receive vivitrol applicable . 10 . Owning cell phone . Participants require phone use someone else 's phone . 1 . Presence serious medical condition would , opinion study physician , make participation medically hazardous ( e.g. , acute hepatitis , unstable cardiovascular , liver renal disease ) . 2 . A current pattern alcohol sedative use , assess study physician , would preclude safe participation study and/or would likely require imminent medical detoxification . 3 . Has undergone one inpatient medical detoxification treatment ; 4 . Lack proficiency English ; 5 . Currently homeless ( unless reside recovery home contact information provide ) ; 6 . Presence clinically significant psychiatric symptom assess MINI , psychosis , acute mania , suicide risk would require immediate treatment make study compliance difficult . 7 . Not currently take naltrexone injectable form ( Vivitrol ) interest taking/receiving information vivitrol interested take vivitrol 8 . Adherent &gt; =90 % antiretroviral therapy regimen , determine medication adherence screen procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HIV+</keyword>
	<keyword>Alcohol dependence</keyword>
	<keyword>Mobile Technology</keyword>
</DOC>